1-6 of 6
Robin Filshie, PhD FRACP
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Efstathios Kastritis, MD, Xavier Leleu, Bertrand Arnulf, MD, Elena Zamagni, María Teresa Cibeira, MD, Fiona Kwok, FRACP, FRCPA, MBBS, Peter Mollee, MBBS, MMedSc, FRACP, FRCPA, Roman Hajek, MD, Philippe Moreau, Arnaud Jaccard, MD PhD, Stefan Schönland, MD, Robin Filshie, PhD FRACP FRCPA, Emmanuelle Nicolas-Virelizier, MD, Bradley Augustson, Maria-Victoria Mateos, MD PhD, Ashutosh Wechalekar, MD FRCPath, Eric Hachulla, MD PhD, Paolo Milani, MD, Meletios A Dimopoulos, Jean-Paul Fermand, Andrea Foli, MD, Maria Gavriatopoulou, Antonio Palumbo, MD, Pieter Sonneveld, MD PhD, Hans Erik Johnsen, MD DMSc, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD
Journal: Blood
Blood (2016) 128 (22): 646.
https://doi.org/10.1182/blood.V128.22.646.646
Published: 2016
Journal Articles

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Efstathios Kastritis, MD, Xavier Leleu, MD, Bertrand Arnulf, Elena Zamagni, MD, Peter Mollee, M Teresa Cibeira, Stefan O Schönland, Philippe Moreau, MD, Roman Hajek, Arnaud Jaccard, MD, Emmanuelle Nicolas-Virelizier, MD, Robin Filshie, PhD FRACP, Bradley Augustson, MBBS, FRACP, FRCPA, Maria-Victoria Mateos, MD PhD, Paolo Milani, MD, Meletios A. Dimopoulos, Eric Hachulla, MD PhD, Jean-Paul Fermand, MD PhD, Andrea Foli, MD, Antonio Palumbo, MD, Pieter Sonneveld, MDPhD, Hans Erik Johnsen, MD, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD
Journal: Blood
Blood (2014) 124 (21): 35.
https://doi.org/10.1182/blood.V124.21.35.35
Published: 2014
Journal Articles

Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments

Anna Kalff, MBBS, FRACP, FRCPA, Nola Kennedy, Patricia A. Walker, MBBS, FRACP, FRCPA, Tiffany T. Khong, BSc, PhD, Anthony Schwarer, MD, Andrew W. Roberts, MBBS, PhD, Philip Campbell, MBBS, FRACP, FRCPA, Robin Filshie, PhD FRACP, Angela Smiley, Malgorzata Gorniak, Marion Black, Nicole Jenkins, Geoffrey Raines, Andrew Spencer, MBBS FRACP FRCPA MD
Journal: Blood
Blood (2014) 124 (21): 2103.
https://doi.org/10.1182/blood.V124.21.2103.2103
Published: 2014
Journal Articles

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

David T Yeung, BSc, MBBS, FRACP, FRCPA, Michael Philip Osborn, MBBS, Deborah L White, PhD, Susan Branford, PhD, Michael Kornhauser, Cassandra Slader, PhD, Samar Issa, MBChB, FRACP, FRCPA, Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K Arthur, MBBS, FRACP, FRCPA, Yiu Lam Kwan, MBBS FRACP FRCPA, Cecily J Forsyth, FRACP, FRCPA, David Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS, on Behalf Of ALLG
Journal: Blood
Blood (2012) 120 (21): 3771.
https://doi.org/10.1182/blood.V120.21.3771.3771
Published: 2012
Journal Articles

Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial

David T. Yeung, BSc, MBBS, FRACP, FRCPA, Michael Osborn, MBBS, FRACP, FRCPA, Deborah L. White, PhD. FFSc(RCPA), Susan Branford, PhD, Michael Kornhauser, Cassandra Slader, PhD, Samar Issa, FRACP, FRCPA, Devendra K Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K Arthur, MBBS, FRACP, FRCPA, Yiu Lam Kwan, MBBS FRACP FRCPA, Cecily J Forsyth, FRACP, FRCPA, David Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS, FRACP, FRCPA
Journal: Blood
Blood (2011) 118 (21): 451.
https://doi.org/10.1182/blood.V118.21.451.451
Published: 2011
Journal Articles

Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial

David T. Yeung, MBBS, Michael Osborn, MBBS, FRACP, FRCPA, Deborah L. White, PhD, Susan Branford, PhD, Lauren Haswell, MSci, Cassandra Slader, PhD, Samar Issa, FRACP, FRCPA, Devendra K. Hiwase, MBBS, PhD, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K. Arthur, MBBS, Yiu Lam Kwan, MBBS, FRACP, FRCPA, Cecily J. Forsyth, FRACP, FRCPA, David M. Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS, on Behalf Of ALLG
Journal: Blood
Blood (2010) 116 (21): 209.
https://doi.org/10.1182/blood.V116.21.209.209
Published: 2010